Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 3 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Targeted Therapeutics: Introduction | 6 | 1 |
| GBI Research Guidance | 6 | 1 |
| Targeted Therapeutics: Overview | 7 | 3 |
| Introduction | 7 | 1 |
| Targeted Therapy is the Need of the Hour | 7 | 1 |
| High Side Effects and Toxic Effects of Conventional Therapy | 7 | 1 |
| Variable Efficacy Rate of Conventional Drugs at the Affected Site | 7 | 1 |
| Resistance Developed to Conventional Drugs Used to Treat Infections | 7 | 1 |
| Targeted Therapeutics Market Drivers and Restraints | 8 | 1 |
| Targeted Therapeutics Market Drivers | 8 | 1 |
| Difficult Regulatory Pathway is required to be Followed for the Entry of any Generic into the Market | 8 | 1 |
| Increase in the Number of Patients who are Prescribed Targeted Therapeutics due to Their Higher Efficacy and Specificity | 8 | 1 |
| Increased Faith Shown by Healthcare Professionals in Targeted Therapeutics is Driving the Market to Newer Heights | 8 | 1 |
| Targeted Therapeutics Market Restraints | 9 | 1 |
| Time Lag between Research and Commercialization | 9 | 1 |
| Regulatory Hindrance to Get Approval for Treatment | 9 | 1 |
| High Treatment Cost and Low Patient Compliance | 9 | 1 |
| Targeted Therapeutics: Major Types of Targeted Therapeutics | 10 | 59 |
| Small Molecules | 10 | 1 |
| Overview | 10 | 2 |
| Innovative Small Molecule Therapeutics Market Drivers and Restraints | 12 | 1 |
| Small Molecule Therapeutics Market Drivers | 12 | 1 |
| Increased use of Combination Therapies, which Includes Small Molecules with Biologics | 12 | 1 |
| Increase in R&D for Novel Drug Delivery System, which will Lead to Increase in the Use of Targeted Small Molecule Drugs | 12 | 1 |
| Innovative Small Molecule Therapeutics Market Restraints | 12 | 1 |
| Side Effects of Targeted Small Molecule Drugs will be a Market Restraint | 12 | 1 |
| Drug-Drug Interaction of Small Molecules Leads to Increased Concern over their Use for the Patient Pool who are on Multiple Drugs | 12 | 1 |
| Profiles of Key Pipeline Molecules | 13 | 1 |
| Abiraterone Acetate (J&J) Phase I &III | 13 | 1 |
| BSI-201 with Gemcitabine and Carboplatin (Phase III for Breast Cancer and Lung Cancer; Phase II for Ovarian Cancer) Sanofi-Aventis | 14 | 1 |
| Aliskiren (Phase III for Congestive Heart Failure, Coronary Disease, Atherosclerosis and Phase II for Diabetic Macular Edema) | 15 | 1 |
| Velcade is under Clinical Trials for the Indication of Follicular Non-Hodkin s Lymphoma (NHL) | 16 | 1 |
| Iressa is Undergoing Phase III Trials for Head and Neck Cancer and Phase II Trials for Carcinomas, Malignant Mesothelioma, Breast Cancer, Prostate Cancer, Brain Cancer | 17 | 1 |
| Nexavar with Tarceva is in Phase III Trial for the Treatment of Hepatocellular Carcinoma | 18 | 1 |
| Sutent is in Phase III Trial for Renal Cell Carcinoma Adjuvant | 19 | 1 |
| Telatinib is in Phase II of Development for Gastric Cancer and in Phase I for Colorectal Cancer | 20 | 1 |
| Enzastaurin is in Phase III of Development for Diffuse Large B-Cell Lymphoma | 21 | 1 |
| Votrient (pazopanib) with Tykerb (lapatinib) is in Phase III of Development for the Treatment of Inflammatory Breast Cancer | 22 | 1 |
| Proteins/Peptide Drugs | 23 | 1 |
| Overview | 23 | 2 |
| Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints | 25 | 1 |
| Peptides/Protein Drug Therapeutics Market Drivers | 25 | 1 |
| Protein or Peptide Drugs have more Potential than Small Molecule Drugs | 25 | 1 |
| Low Toxicological Side Effects | 25 | 1 |
| Peptides/Protein Drug Therapeutics Market Restraints | 25 | 1 |
| Low Compliance by Patients due to Mode of Delivery | 25 | 1 |
| High Cost of R&D | 25 | 1 |
| Profiles of Key Pipeline Molecules | 26 | 1 |
| Pamorelin | 26 | 1 |
| Epogin | 26 | 1 |
| AS1411 | 27 | 1 |
| RG 7204 | 28 | 2 |
| Monoclonal Antibodies (MAbs) and Antibody Like Structures | 30 | 1 |
| Overview | 30 | 2 |
| Key Trends which will Decide the Future of the MAb Market | 32 | 1 |
| Monoclonal Antibody Therapeutics, Market Drivers and Restraints | 33 | 1 |
| Monoclonal Antibody Therapeutics Market Drivers | 33 | 1 |
| Rapid Uptake of Monoclonal Antibodies has Driven the Monoclonal Antibody Sales Growth | 33 | 1 |
| Improved Side Effects Profiles and Tolerance of Monoclonal Antibodies Therapy | 33 | 1 |
| Lack of Effective Conventional Therapies Accelerates Utilization of Monoclonal Antibodies | 34 | 1 |
| Expanded Indications Open up New Potential Patient Groups | 34 | 1 |
| Lack of Generics Augmented the Sales Growth of Monoclonal Antibodies | 34 | 1 |
| Global Monoclonal Antibody Market Restraints | 35 | 1 |
| High Cost of Monoclonal Antibodies Hampering the Growth of the Treatment Population | 35 | 1 |
| Adverse Effects Generation of Antibodies against Monoclonal Antibodies in Patients Receiving Monoclonal Antibody Therapy | 35 | 1 |
| Industry Challenges Majority of MAbs Receive Approval as Last Option Therapies | 35 | 1 |
| Profiles of Key Pipeline Molecules (MAb) | 35 | 1 |
| CP-751,871 (figitumumab) | 35 | 1 |
| MK-0646 (dalotuzumab) | 36 | 1 |
| SGN-35 (brentuzimab vedotin) | 36 | 1 |
| Trastuzumab-DM1 (T-DM1) | 37 | 1 |
| CMC544 (inotuzumab ozogamcin) | 37 | 1 |
| Arzerra (ofatumumab) | 37 | 1 |
| Galiximab | 38 | 1 |
| Benlysta | 38 | 1 |
| ABT-874 | 39 | 1 |
| Alemtuzumab | 40 | 1 |
| MEDI-528 | 41 | 1 |
| ABthrax | 41 | 1 |
| Numax (motavizumab) | 42 | 1 |
| TB-402 | 42 | 1 |
| RNA Interference | 43 | 1 |
| Overview | 43 | 1 |
| RNA Interference Therapeutics Market Drivers and Restraints | 43 | 1 |
| RNA Interference Therapeutics Market Drivers | 43 | 1 |
| Dual Mechanism of Action is the Major Factor Driving RNA Therapeutics Market Potential | 43 | 1 |
| Failure of Conventional Therapies in Curing Chronic Diseases has Created High Unmet Needs | 44 | 1 |
| Major Breakthrough Technologies in RNA Research and Development Opened up New Markets | 44 | 1 |
| Increased Funding for RNA Research by Major Countries such as the US and Europe | 44 | 1 |
| RNA Interference Therapeutics Market Restraints | 44 | 1 |
| Many RNA Therapies are Failing at Phase III Clinical Development | 44 | 1 |
| The Characteristics of RNA Structure make them Vulnerable to Human Enzymes | 45 | 1 |
| Lack of Effective Delivery Technologies that can Deliver RNA Therapies to the Target Site are making RNA Therapies Ineffective | 45 | 1 |
| RNA Therapies Can Cause Potential Side-Effects and Off-Target Effects | 45 | 1 |
| Profiles of Key Pipeline Molecules (RNA) | 45 | 1 |
| Mipomersen | 45 | 1 |
| LOR-2040 | 46 | 1 |
| Genasense | 47 | 1 |
| ProSavin | 48 | 1 |
| Trovax | 49 | 1 |
| Trabedersen | 50 | 1 |
| Onconase | 50 | 1 |
| Alicaforsen | 51 | 2 |
| Stem Cell Therapies | 53 | 1 |
| Overview | 53 | 1 |
| Stem Cell Therapeutics Market Drivers and Restraints | 54 | 1 |
| Stem Cell Therapeutics Market Drivers | 54 | 1 |
| Supporting Political Environment on Embryonic Stem Cell Research will Advance the Stem Cell Industry to Prosper in the US | 54 | 1 |
| Limited Availability of Treatments to Treat Certain Disease Conditions Increases Market Opportunity for Stem Cell Research | 54 | 1 |
| Stem Cell Therapeutics Market Restraints | 55 | 1 |
| Stem Cell Research and Development is an Expensive Process which Requires Considerable Funding to Operate | 55 | 1 |
| Availability of Adequate Reimbursements is Unclear and Leads to a Conundrum | 55 | 1 |
| Ethical, Legal and Social Issues Persist and Act as a Challenge | 55 | 1 |
| Identifying, recruiting and retaining the best scientific talents is an intractable process for stem cell research based companies | 55 | 1 |
| Profile of Key Late Stage Therapies | 56 | 1 |
| Prochymal | 56 | 1 |
| Myocell | 56 | 1 |
| Aldagen ALD-101 | 56 | 1 |
| Ontaril (CX401) | 56 | 1 |
| StemEx | 56 | 1 |
| Bone Repair Cells | 56 | 1 |
| ALD 301 | 57 | 1 |
| Cardiac Repair Cells and Vascular Repair Cells | 57 | 1 |
| Myoblast Therapy | 57 | 1 |
| Allogenic Mesenchymal Precursor cells (MPC) and Autologous Mesenchymal Precursor cells | 57 | 1 |
| Autologous Cellular Therapy CD34 (ACT34-CMI) | 57 | 1 |
| Allogeneic Adult Mesenchymal Precursor cells | 57 | 1 |
| Chondrogen | 57 | 1 |
| PLX-PAD | 57 | 1 |
| TCA Cellular Therapy Autologous Adult stem cells | 58 | 1 |
| Gene Therapy | 58 | 1 |
| Overview | 58 | 1 |
| Gene Therapy Market Drivers and Restraints | 58 | 1 |
| Gene Therapy Market Drivers | 59 | 1 |
| Modification of DNA for the Treatment of Diseases | 59 | 1 |
| High Prevalence of Complex and Difficult to Treat Diseases | 59 | 1 |
| Gene Therapy Market Restraints | 59 | 1 |
| Toxicological Complications due to Improper Insertion of Genes | 59 | 1 |
| Stringent Regulatory Policies Makes Approval a Complex Process | 59 | 1 |
| Ethical Issues Involving Germ-line Cells | 59 | 1 |
| Key Pipeline Candidates | 60 | 1 |
| AAV-hAADC-2 | 60 | 1 |
| Glybera with Cellcept with Neoral (Phase III) | 61 | 1 |
| Glybera with CellCept, Neoral and Solumedrol (Phase III) | 62 | 1 |
| AMT-060 (Phase II) | 63 | 1 |
| AAV-GAD (Phase II) | 63 | 1 |
| Cell Based Gene Therapy (Phase II) | 64 | 1 |
| MSP-36 (Pre-clinical) | 65 | 1 |
| DWP418 (Phase I) | 66 | 1 |
| Hemophilia A Gene Therapy (Pre-clinical) | 66 | 1 |
| Non-Viral Gene Therapy (Phase II) | 67 | 2 |
| Targeted Therapeutics: Regulatory Landscape | 69 | 3 |
| The US Regulatory Landscape Scenario | 69 | 1 |
| National Institute for Health (NIH) | 69 | 1 |
| FDA | 69 | 1 |
| EU Regulatory Landscape Scenario | 70 | 1 |
| Committee for Advanced Therapies (CAT) | 70 | 2 |
| Targeted Therapeutics: Competitive Landscape | 72 | 22 |
| Antisoma | 72 | 1 |
| Overview | 72 | 1 |
| Key Deals | 72 | 1 |
| Antisoma Acquired Aptamera in January 2005 | 72 | 1 |
| Antisoma Acquires Xanthus Pharmaceuticals in November 2008 | 72 | 1 |
| AVI BioPharma | 72 | 1 |
| Overview | 72 | 1 |
| Key Deals | 73 | 1 |
| AVI BioPharma Enters Into Agreement with Action Duchenne in July 2009 | 73 | 1 |
| AVI BioPharma Acquires Ercole Biotech in March 2008 | 73 | 1 |
| AVI BioPharma Enters Into Licensing Agreement with Eleos in January 2007 | 73 | 1 |
| Biogen | 73 | 1 |
| Overview | 73 | 1 |
| Key Deals | 74 | 1 |
| Biogen Idec Amends its Collaboration with Genentech for GA101 in October 2010 | 74 | 1 |
| Biogen Idec Enters Into Licensing Agreement with Knopp Neurosciences for KNS-760704 in August 2010 | 74 | 1 |
| Cephalon | 74 | 1 |
| Overview | 74 | 1 |
| Key Deals | 75 | 1 |
| Cephalon Enters into Licensing Agreement with Mesoblast in December 2010 | 75 | 1 |
| Cephalon Acquires Mepha Pharma in April 2010 | 75 | 1 |
| Cephalon Acquires Ception Therapeutics in April 2010 | 75 | 1 |
| Cephalon Acquired Arana Therapeutics in August 2009 | 75 | 1 |
| Celator Pharmaceuticals Enters Into Research Agreement with Cephalon in May 2009 | 76 | 1 |
| Eli Lilly | 76 | 1 |
| Overview | 76 | 1 |
| Key Deals | 76 | 1 |
| Adimab Enters Into Licensing Agreement with Eli Lilly in December 2010 | 76 | 1 |
| Eli Lilly Acquires Alnara Pharmaceuticals in July 2010 | 77 | 1 |
| Molecular Templates Enters Into Drug Discovery Collaboration with ImClone Systems in July 2010 | 77 | 1 |
| Eli Lilly Acquires ImClone Systems in November 2008 | 77 | 1 |
| United Therapeutics Enters Into Licensing Agreement with Eli Lilly in November 2008 | 78 | 1 |
| Forest Laboratories | 78 | 1 |
| Overview | 78 | 1 |
| Key Deals | 78 | 1 |
| In December 2010, Gruenenthal Enters Into Licensing Agreement with Forest Laboratories Ireland for GRT 6005 | 78 | 1 |
| TransTech Pharma Enters Into Licensing Agreement with Forest Laboratories | 79 | 1 |
| Genmab | 79 | 1 |
| Overview | 79 | 1 |
| Key Deals | 79 | 1 |
| Genmab Enters Into Co-Development Agreement with H. Lundbeck in October 2010 | 79 | 1 |
| Genmab Enters Into Research Collaboration with Seattle Genetics in September 2010 | 80 | 1 |
| Gilead Sciences | 80 | 1 |
| Overview | 80 | 1 |
| Key Deals | 80 | 1 |
| Gilead Acquired CGI Pharmaceuticals in July 2010 | 80 | 1 |
| Gilead Sciences Acquired CV Therapeutics in April 2009 | 81 | 1 |
| Gilead Acquired Myogen in November 2006 | 81 | 1 |
| Hoffmann La- Roche (Genentech) | 82 | 1 |
| Overview | 82 | 1 |
| Key Deals | 82 | 1 |
| NovImmune Enters Into Licensing Agreement with Genentech in July 2010 | 82 | 1 |
| A-CUBE Enters Into Collaboration with Chugai Pharmaceutical (Roche) in December 2010 | 82 | 1 |
| Adimab Enters Into Licensing Agreement with Genentech (Roche) in December 2010 | 83 | 1 |
| Horizon Discovery Enters Into Co-Development Agreement with Genentech in April 2009 | 83 | 1 |
| ImmunoGen Enters Into Licensing Agreement with Genentech in December 2008 | 83 | 1 |
| Isis Pharmaceuticals | 84 | 1 |
| Overview | 84 | 1 |
| Key Deals | 84 | 1 |
| Isis Pharmaceuticals Enters Into Collaboration with Xenon Pharmaceuticals in November 2010 | 84 | 1 |
| GlaxoSmithKline Entered Into Licensing Agreement with Isis Pharmaceuticals in March 2010 | 85 | 1 |
| Alnylam Pharmaceuticals Entered Into Licensing Agreement with Isis Pharmaceuticals in April 2009 | 85 | 1 |
| Isis Pharmaceuticals Entered Into Licensing Agreement with Genzyme in June 2008 | 85 | 1 |
| Isis Pharmaceuticals Acquired Symphony GenIsis in September 2007 | 86 | 1 |
| Isis Acquired Orasense and HepaSense from Elan in June 2004 | 86 | 1 |
| Johnson and Johnson (J&J) | 86 | 1 |
| Overview | 86 | 1 |
| Key Deals | 87 | 1 |
| Anchor Therapeutics Enters Into Collaboration and Licensing Agreement With Ortho-McNeil-Janssen in September 2010 | 87 | 1 |
| Oncodesign Enters Into Licensing Agreement with Janssen Pharmaceutica in June 2010 | 87 | 1 |
| Edison Pharmaceuticals Enters Into Licensing Agreement with Centocor in January 2010 | 87 | 1 |
| Xencor Enters Into Licensing Agreement with Centocor in November 2009 | 88 | 1 |
| Johnson &Johnson Acquires Assets and Rights to Alzheimer s Immunotherapy Program from Elan in September 2009 | 89 | 1 |
| Horizon Discovery Signs Licensing Agreement with Ortho Biotech Oncology Research &Development | 89 | 1 |
| Johnson &Johnson Completes Acquisition of Cougar Biotechnology in July 2009 | 89 | 1 |
| Mesoblast Limited | 90 | 1 |
| Overview | 90 | 1 |
| Key Deals | 90 | 1 |
| Mesoblast Receives Anti-Trust Approval to Acquire Angioblast Systems in 2010 | 90 | 1 |
| Pfizer | 90 | 1 |
| Overview | 90 | 1 |
| Key Deals | 90 | 1 |
| Lpath Enters Into Licensing Agreement with Pfizer in December 2010 | 90 | 1 |
| Ablexis Enters Into Licensing Agreement with Pfizer And Four Other Pharma Companies | 91 | 1 |
| Pfizer Enters Into Co-Development Agreement with Debiopharm in January 2010 | 91 | 1 |
| Ensemble Discovery Enters Into Co-Development Agreement with Pfizer in January 2010 | 91 | 1 |
| Compugen Enters Into Collaboration Agreement with Pfizer in December 2009 | 91 | 1 |
| Athersys Enters Into Co-Development Agreement with Pfizer in December 2009 | 92 | 1 |
| Adimab Enters Into Co-Development Agreement with Pfizer in December 2009 | 92 | 1 |